BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS: We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. RESULTS: Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. CONCLUSIONS: Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
BACKGROUND:Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS: We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. RESULTS: Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. CONCLUSIONS:Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade ≥ 3 arterial or venous thromboembolic events, GI perforation, or fatal events.
Authors: L Manso; F Moreno; R Márquez; B Castelo; A Arcediano; M Arroyo; A I Ballesteros; I Calvo; M J Echarri; S Enrech; A Gómez; R González Del Val; E López-Miranda; M Martín-Angulo; N Martínez-Jañez; C Olier; P Zamora Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Javier Cortés; Emiliano Calvo; Antonio González-Martín; Shaheenah Dawood; Antonio Llombart-Cussac; Leticia De Mattos-Arruda; Patricia Gómez; Orlando Silva; Edith A Perez; Hope S Rugo; Ana Lluch; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Michael LeBlanc; Brent Farnsworth; Maria Iannone; Martha J Glenn; Richard I Fisher; Thomas P Miller Journal: Blood Date: 2012-06-25 Impact factor: 22.113
Authors: Miguel Manuel Murillo; Santiago Zelenay; Emma Nye; Esther Castellano; Francois Lassailly; Gordon Stamp; Julian Downward Journal: J Clin Invest Date: 2014-07-08 Impact factor: 14.808